ArticleMicrobial cell factories2023
Exopolysaccharides from vaginal lactobacilli modulate microbial biofilms.
Article in Microbial cell factories, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Activity ofVirulence · 2026Article
- Tiered Functional Screening Identifies an Autochthonous VaginalMicroorganisms · 2026Article
- Multi-Analytical Approach for the Quality and Functional Evaluation of Probiotic Formulations: The Case of Lactobacillus acidophilus LA-5Probiotics and antimicrobial proteins · 2026Article
- Effect of Lactiplantibacillus Plantarum THK-J112 Against Candida Overgrowth in Acne Complications.Probiotics and antimicrobial proteins · 2026Article
- Exopolysaccharides of Lactobacillus crispatus mediate key balancing interactions with the vaginal mucosa.NPJ biofilms and microbiomes · 2026Article
- Fluconazole-Decorated Gold Nanoparticles as a Novel Therapeutic Strategy Against Carbapenem-ResistantInfection and drug resistance · 2026Article
- Targeting vaginal dysbiosis: prospects for the application of live biotherapeutics products.Frontiers in microbiology · 2026Review
- New Strategies for Preventing Perinatal Group B Streptococcus (GBS) Infections.Pathogens (Basel, Switzerland) · 2025Review
- VaginalBiofilm · 2025Article
- Agave Fructans as a Carbon Source to Develop a Postbiotic-Based Strategy for the Prophylaxis and Treatment ofInternational journal of molecular sciences · 2025Article
- Perspectives on Vaginal Ecology and Management of Recurrent Vulvovaginal Candidiasis: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Functional and Safety Profile ofPharmaceutics · 2025Article
- Extracellular polymeric substances in indigenous microalgal-bacterial consortia: advances in characterization techniques and emerging applications.World journal of microbiology & biotechnology · 2025Review
- Transformative strategies for saline soil restoration: Harnessing halotolerant microorganisms and advanced technologies.World journal of microbiology & biotechnology · 2025Review
- Methods for Detection, Extraction, Purification, and Characterization of Exopolysaccharides of Lactic Acid Bacteria-A Systematic Review.Foods (Basel, Switzerland) · 2024Review
- The Gut Microbiota Mediates the Protective Effects of Spironolactone on Myocardial Infarction.Journal of microbiology (Seoul, Korea) · 2024Article
- A Comprehensive Overview of Postbiotics with a Special Focus on Discovery Techniques and Clinical Applications.Foods (Basel, Switzerland) · 2024Review
- Advances in Microbial Exopolysaccharides: Present and Future Applications.Biomolecules · 2024Review
- Protective Mechanisms of Vaginal Lactobacilli against Sexually Transmitted Viral Infections.International journal of molecular sciences · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExopolysaccharides (EPS) secreted by beneficial lactobacilli exert a plethora of positive activities, but little is known about their effects on biofilms of opportunistic vaginal pathogens and especially on biofilms of lactobacilli themselves. Here, the EPS produced by six vaginal lactobacilli, belonging to Lactobacillus crispatus (BC1, BC4, BC5) and Lactobacillus gasseri (BC9, BC12, BC14) species were isolated from cultural supernatants and lyophilized.
resultsLactobacillus EPS were chemically characterized in terms of monosaccharide composition by liquid chromatography (LC) analysis coupled to UV and mass spectrometry (MS) detection. Moreover, the ability of EPS (0.1, 0.5, 1 mg/mL) to stimulate the biofilm formation of lactobacilli and to inhibit the formation of pathogens' biofilms was evaluated by crystal violet (CV) staining and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. Isolated EPS (yields 133-426 mg/L) were heteropolysaccharides mainly composed of D-mannose (40-52%) and D-glucose (11-30%). For the first time we demonstrated that Lactobacillus EPS were able to stimulate in a dose-dependent manner (p < 0.05) the formation of biofilms of ten strains belonging to L. crispatus, L. gasseri and Limosilactobacillus vaginalis species, in terms of cell viability (84-282% increase at 1 mg/mL) and especially biofilm biomass (40-195% increase at 1 mg/mL), quantified with MTT assay and CV staining, respectively. EPS released from L. crispatus and L. gasseri were found to better stimulate the biofilms of the same producer species rather than that of other species, including producing strains themselves and other strains. Conversely, the biofilm formation of bacterial (Escherichia coli, Staphylococcus spp., Enterococcus spp. and Streptococcus agalactiae) and fungal (Candida spp.) pathogens was inhibited. The anti-biofilm activity was dose-dependent and was more marked for L. gasseri-derived EPS (inhibition up to 86%, 70%, and 58% at 1 mg/mL, 0.5 mg/mL, and 0.1 mg/mL, respectively), whilst L. crispatus-derived EPS resulted overall less efficient (inhibition up to 58% at 1 mg/mL and 40% at 0.5 mg/mL) (p < 0.05).
conclusionsLactobacilli-derived EPS favour the biofilm formation of lactobacilli preventing, at the same time, that of opportunistic pathogens. These results support the possible employment of EPS as postbiotics in medicine as a therapeutic/preventive strategy to counteract vaginal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.